U.S. markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
159.29+2.02 (+1.28%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close157.27
Open158.44
Bid150.00 x 800
Ask161.70 x 900
Day's Range155.07 - 161.01
52 Week Range55.90 - 163.42
Volume926,015
Avg. Volume1,017,408
Market Cap15.925B
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-1.93
Earnings DateFeb 22, 2021 - Feb 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est150.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer
    Business Wire

    Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer

    Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021.

  • The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
    Benzinga

    The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) * AbbVie Inc (NYSE: ABBV) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * AtriCure Inc. (NASDAQ: ATRC) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BIOLASE Inc (NASDAQ: BIOL) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) * CareDx Inc (NASDAQ: CDNA) * Celsius Holdings, Inc. (NASDAQ: CELH) * DermTech Inc (NASDAQ: DMTK) * Dyne Therapeutics Inc (NASDAQ: DYN) * Edap Tms SA (NASDAQ: EDAP) * Evelo Biosciences Inc (NASDAQ: EVLO) * EXACT Sciences Corporation (NASDAQ: EXAS) * Eyenovia Inc (NASDAQ: EYEN) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Guardant Health Inc (NASDAQ: GH) (reacted to presentation at the JPMorgan Healthcare Conference) * Intra-Cellular Therapies Inc (NASDAQ: ITCI) * Kaleido Biosciences Inc (NASDAQ: KLDO) * Laboratory Corp. of America Holdings (NYSE: LH) * Merus NV (NASDAQ: MRUS) (announced presentation of Phase 1 data for MCLA-158 in metastatic colorectal cancer) * OncoSec Medical Inc (NASDAQ: ONCS) * Pacira Biosciences Inc (NASDAQ: PCRX) * PRA Health Sciences Inc (NASDAQ: PRAH) * Provention Bio Inc (NASDAQ: PRVB) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * Syneos Health Inc (NASDAQ: SYNH) * Travere Therapeutics Inc (NASDAQ: TVTX) * Vericel Corp (NASDAQ: VCEL) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Jan. 12) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Lexaria Bioscience Corp. (LXRP) (the company's shares uplisted to Nasdaq and it also announced a $9.6 million public offering) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus Acorda to Sell Parkinson's Disease Drug Manufacturing Facility, Reduce 16% of Workforce Acorda Therapeutics Inc (NASDAQ: ACOR) announced a definitive agreement to sell its Inbrija manufacturing operations in Chelsea, Massachusetts to Catalent Inc (NYSE: CTLT) for $80 million in cash.In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package Inbrija for Acorda. As part of the deal, Catalent will absorb all Acorda employees who work at the Chelsea facility, and certain Acorda employees at the company's Waltham, Massachusetts facility.Acorda also announced a corporate restructuring to reduce costs and focus its resources on Imbrija. In addition to the associates who will transition to Catalent, Acorda is reducing its combined Ardsley, Waltham and field headcount by approximately 16% through a reduction in force.Acorda also said it entered into an at-the-market offering agreement with H.C. Wainwright & Co., for offering common stock having an aggregate value of up to $15.25 million.Acorda shares jumped 59.91% to $6.78 in premarket trading Wednesday.Morphosys, Incyte Announce Canadian Regulatory Submission For Blood Cancer Combo Treatment Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said Health Canada has accepted the new drug submission for tafasitamab, an anti-CD19 antibody, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.Incyte has exclusive commercialization rights for tafasitamab outside of the U.S. and, if approved, Incyte will hold the marketing authorization for tafasitamab in Canada.Travere Gets Orphan Drug Designation For Sparsentan In Rare Kidney Disorder Travere announced that the FDA has granted orphan drug designation to sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that causes end-stage kidney disease. Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021.DermTech's Non-invasive Melanoma Genomic Test Recommended by National Comprehensive Cancer Network DermTech said non-invasive genomic patch testing for melanoma, like DermTech's pigmented lesion assay, has received a recommendation from the National Comprehensive Cancer Network. The recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Clinical Practice Guidelines in Oncology for cutaneous melanoma recognize the use of noninvasive genomic patch testing to help guide biopsy decisions for cutaneous melanoma.The stock gained 12.46% to $41.61 in after-hours trading.Amgen In-licenses Autoimmune Disorder Programs For Over $240M Amgen, Inc. (NASDAQ: AMGN) executed a license and collaboration agreement with EVOQ Therapeutics for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the agreement, Amgen and EVOQ will collaborate on preclinical development and Amgen will be responsible for clinical development and commercialization.In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies.Mersana Shares Gain On Insider Buying Mersana Therapeutics Inc (NASDAQ: MRSN) shares gained after a filing with the SEC revealed that Andrew Hack, a member of the board, bought 250,000 shares in the company.The stock added 7.34% to $19.45 in after-hours trading.Preannouncements Ahead of the presentation at the JPMorgan Health Conference Bausch Health Companies Inc (NYSE: BHC) said it expects fourth-quarter revenues to be greater than $2.20 billion. For the full year of 2020, the company expects to report revenues above the high-end of its revenue guidance range of $7.8 billion-$8 billion.Analysts, on average, estimate expect revenues of $2.12 billion for the fourth quarter and $7.94 billion for the full year.The company also guided to strong adjusted EBITDA.In after-hours trading, the stock rose 5.67% to $24.80.Neuronetics Inc (NASDAQ: STIM) preannounced fourth-quarter revenues of $15 million to $15.5 million, ahead of the guidance of $13 million and $13.5 million. For the full year, revenues are estimated between $48.7 million and $49.2 million. The consensus estimates call for revenues of $13.24 for the fourth quarter and $46.93 for the full year.The stock rallied 14.82% to $13.40 in after-hours trading.Clearpoint Neuro Inc (NASDAQ: CLPT) preannounced above-consensus revenues for the fourth quarter and full year.The stock was up 3.43% to $15.99 in after-hours trading.Offerings Provention Bio Inc (NASDAQ: PRVB) said it has commenced an underwritten public offering of 6 million shares of its common stock. All of the shares to be sold in the offering are to be sold by the company.The stock fell 10.03% to $17.50 in after-hours trading.Affimed NV (NASDAQ: AFMD) announced the commencement of an underwritten public offering of its common shares. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the company added.In the after-hours session, the stock slipped 7.85% to $6.10.See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue * The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 12 Best Telemedicine Stocks to Buy Now
    Insider Monkey

    12 Best Telemedicine Stocks to Buy Now

    In this article, we present to you the 12 best telemedicine stocks to buy now according to hedge funds. If you’re in a hurry you can skip ahead to the 5 best telemedicine stocks to buy now. The World Health Organization defines Telehealth as the delivery of health care services, where patients and providers are […]